Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

CB Reporter

Retinal Vein Occlusion Phase III Drugs Market Growth by 2020 ...
CB Reporter
Retinal Vein Occlusion Phase III Drugs Market – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 report provides comprehensive ...
Varicose veins and spider veins | womenshealth.govWomen's Health.gov
Varicose Veins | Society for Vascular SurgerySociety for Vascular Surgery
What is bioimpedance? - Department of Physics - UiOUiO
NCBI - NIH
all 35 news articles »

Retinal Vein Occlusion Market move up at a CAGR of 11.2% by Topmost Players | By Types Branch Retinal Artery ...
MENAFN.COM
(MENAFN Editorial) Complete Study of 'Retinal Vein Occlusion Market' Research Report is added on MarketResearchFuture.com with Latest Advancement. Report covered In a Segregated way like Segmentation with sub segments, Growth Barrier, Major ...

and more »

Retinal Vein Occlusion Market Share Analysis 2018 | Registering 11.2% of A CAGR with Renowned Players ...
MENAFN.COM
(MENAFN Editorial) This report provides in-depth qualitative and overall analysis of the' Retinal Vein Occlusion Market' on a regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and ...
Retinal Vein Occlusion Therapeutics Market Report: Analysis of Effective Business Strategies 2013 to 2018thebusinesstactics.com

all 3 news articles »

Global Retinal Vein Occlusion Therapeutics Market Outlook 2018-2025 : Acucela Inc, Addmedica SAS, Aerpio ...
Three PM News (blog)
Global Retinal Vein Occlusion Therapeutics Market 2018. The global “ Retinal Vein Occlusion Therapeutics ” report is a scrupulous study of the global Retinal Vein Occlusion Therapeutics illustrating the up-to-date details in the market. It also ...

and more »

Fitch Solutions (press release)

Filgotinib On Course To Bring Autoimmune Rewards To Galapagos And Gilead
Fitch Solutions (press release)
There was one case of non-serious retinal vein occlusion in the filgotinib 200mg group and no reports of deep venous thrombosis or pulmonary embolism. There were no deaths, malignancies, gastrointestinal perforations, or opportunistic infections ...


Worldwide Retinal Vein Occlusion Therapeutics Market by 2023 Opportunities, Strategies, Challenges, Supply ...
Trade Market Research
Retinal Vein Occlusion Therapeutics Market Report offers a comprehensive study including companies products, applications and Forecast 2013 to 2023 of Retinal Vein Occlusion Therapeutics industry. Retinal Vein Occlusion Therapeutics Market report also ...

and more »

Retinal Vein Occlusion Therapeutics Market Segmentation and Analysis by Recent Trends, Development and Growth ...
Newszak (blog)
Global Retinal Vein Occlusion Therapeutics Market research report will help you take informed decisions, understand opportunities, plan effective business strategies, plan new projects, analyse drivers and restraints and give you a vision on the ...


Marea Informative

Federated Investors Inc. PA Has $868000 Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 108 news articles »

The BMJ

Arteriovenous malformation of the iris
The BMJ
An important differential diagnosis is neovascularisation of the iris, also known as “rubeosis iridis,” resulting from retinal ischaemia caused by conditions such as proliferative diabetic retinopathy and retinal vein occlusion. Other possible causes ...


Daily Industry Reports

Retinal Vein Occlusion Market Symptoms, Transmission, Diagnosis, Treatment and Prevention 2018
Daily Industry Reports
Global Retinal Vein Occlusion Market Research Report 2018- This report studies the global Retinal Vein Occlusion Market status and forecast, categorizes the global Retinal Vein Occlusion market size (value & volume) by manufacturers, type, application, ...

and more »

Nasdaq

Regeneron Gains on Eylea, Dupixent and Pipeline Progress
Nasdaq
Eylea is approved in the United States, EU, Japan and other countries for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and ...

and more »

Daily Industry Reports

Global Retinal Vein Occlusion Therapeutics Market 2018 Leads with Comprehensive Gross Margin by 2025
Daily Industry Reports
The Global Retinal Vein Occlusion Therapeutics Market research 2018 report provides concentrated and in-depth analysis of the existing situation of the Global Retinal Vein Occlusion Therapeutics industry, along with market share, revenue, assertive ...

and more »

Economic Times

High systolic BP affects your retina and may lead to complete vision loss
Economic Times
In fact, patients who suffer from continuous high systolic blood pressure are 280% more prone to developing severe eye conditions like Central Retinal Vein Occlusion, a condition wherein the central vision is affected leading to loss of sight, than ...


Atlanta Business Chronicle

Alpharetta biopharmaceutical company names GC & chief compliance officer
Atlanta Business Chronicle
Clearside Biomedical is developing treatments that restore and preserve vision for people with eye diseases where macular edema is a common complication, including uveitis, retinal vein occlusion and diabetic macular edema. The company's proprietary ...
Clearside Biomedical Inc (CLSD) Given Average Rating of “Buy” by BrokeragesBaseball Daily News

all 4 news articles »

Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron
Seeking Alpha
Recall that Eylea is a treatment for 1) wet age-related macular degeneration (wAMD), 2) diabetic macular edema (DME) and diabetic retinopathy (DR) in DME, and 3) macular edema following retinal vein occlusion (RVO). Eylea is administered via ocular ...


Retinal Vein Occlusion Market 2016 Current Trends, Business Opportunities and Forecast 2027
Fair Reporter
Retinal Vein Occlusion market analyses the Present and future prospects of the Retinal Vein Occlusion market worldwide. Retinal Vein Occlusion Market Growth, Future Prospects and Competitive Analysis, 2016–2027 offers strategic insights into the ...


Morse Asset Management Inc Has $2.09 Million Stake in Regeneron Pharmaceuticals Inc (REGN)
Marea Informative (blog)
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Global Retinal Vein Occlusion Therapeutics Market 2018: Comprehensive Healthcare Research 2025
faircolumnist.com
The Global Retinal Vein Occlusion Therapeutics Market report is a compilation of quantitative and qualitative estimation by industry analysis, industry contender across the value chain, empirical enlightenment, and details from industry experts. The ...

and more »

MD Magazine

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
BioSpace (press release) (blog)
EYLEA® (aflibercept) Injection is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy ...
FDA to Review Injection Treatment for Diabetic RetinopathyPharmacy Times
FDA Accepts Aflibercept Application for Diabetic RetinopathyMD Magazine
Regeneron (REGN) Says FDA to Review EYLEA Injection for Treatment of Diabetic RetinopathyStreetInsider.com

all 6 news articles »

mymarketgazette.com

Global and China Retinal Vein Occlusion Therapeutics Market Research 2018 : Key Companies Addmedica SAS ...
mymarketgazette.com
The Global and China Retinal Vein Occlusion Therapeutics Market research 2018 report provides concentrated and in-depth analysis of the existing situation of the Global and China Retinal Vein Occlusion Therapeutics industry, along with market share, ...


Clearside Biomedical: Buy Or Sell Before 2018 Catalysts
Seeking Alpha
The 8-week data from the first phase 3 trial (SAPPHIRE) in treating macular edema due to retinal vein occlusion is expected in Q4 (a big binary event for the stock). Based on the borderline statistical significance in the phase 2 trial, I consider it a ...
Clearside Biomedical to Participate in 2018 Janney Healthcare ConferenceP&T Community
Clearside Biomedical (NASDAQ:CLSD) Receiving Somewhat Positive Press Coverage, Study FindsFairfield Current

all 8 news articles »

Global Retinal Vein Occlusion Therapeutics Market 2023: Product Overview and Scope, Growth Rate and Price ...
managementjournal24.com
Retinal Vein Occlusion Therapeutics Market report advantages the firms to well appreciate market opportunities and clear severe industry policies. Global companies are growing their existence; native vendors have resulted in it tough to contest with ...


FDA Accepts sBLA of Injection Treatment for Diabetic Retinopathy
Specialty Pharmacy Times
EYLEA is administered as a 2-mg intravitreal injection and is indicated to treat wet age-related macular degeneration, macular edema following retinal vein occlusion, DME, and DR in patients with DME. Aflibercept is contraindicated in patients with ...
FDA to Review Eylea for the Treatment of Non-Proliferative Diabetic RetinopathyMonthly Prescribing Reference

all 4 news articles »

A potential new way to treat some of the most common blinding diseases
Science Daily
... with diabetic retinopathy, the leading cause of blindness in working age adults in the United States, and may also lead to new treatments for uveitis, a spectrum of diseases that leads to inflammation of the eye, as well as for retinal vein and ...


LWW Journals

For Your Patients-Parkinson's Disease Changes: Retinal Imaging May Detect Pathologic Changes in Early Stages of ...
LWW Journals
People with ophthalmic conditions that could affect retinal thickness were excluded such as age-related macular degeneration, glaucoma diabetic retinopathy, and retinal vein or artery occlusion. A movement disorders specialist diagnosed patients with ...


European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for ...
PR Newswire (press release)
In patients with BRAF mutation-positive melanoma across multiple clinical trials, 0.1% of patients experienced retinal vein occlusion (RVO). Permanently discontinue MEKTOVI in patients with documented RVO. In COLUMBUS, uveitis, including iritis and ...

and more »

Energy News

Global Retinal Vein Occlusion Therapeutics Market Outlook 2018- Ohr Pharmaceutical Inc, Regeneron ...
Energy News
The report on the global “Retinal Vein Occlusion Therapeutics market” offers detailed data on the Retinal Vein Occlusion Therapeutics market. Elements such as dominating companies, classification, size, business atmosphere, SWOT analysis, and most ...


Positive PEACHTREE Data to be Highlighted at EURETINA 2018
P&T Community
Clearside's pipeline includes advanced and pre-clinical product candidates in diseases where macular edema is a common complication, including uveitis, retinal vein occlusion (“RVO”) and diabetic macular edema (“DME”). Clearside's most advanced ...

and more »

Gilead And Galapagos Announce Filgotinib Meets Primary And All Key Secondary Endpoints In First Phase 3 Study In ...
Clinical Leader
Two major adverse cardiovascular events (MACE) were identified, one subarachnoid hemorrhage in the placebo group and one myocardial ischemia in the filgotinib 100 mg group. There was one case of non-serious retinal vein occlusion in the filgotinib 200 ...


Data From Clearside Biomedical's Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non ...
Nasdaq
Clearside's pipeline includes advanced and pre-clinical product candidates in diseases where macular edema is a common complication, including uveitis, retinal vein occlusion ("RVO") and diabetic macular edema ("DME"). Clearside's most advanced ...
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Clearside Biomedical (NASDAQ:CLSD) Stock PricePressOracle

all 4 news articles »
» Load more